Comparing Chemoradiation With Fluoropyrimidine Alone Versus Fluoropyrimidine Plus Oxaliplatin for Distal Rectal Cancer
A Multi-center Randomized Trial of Organ Preservation Using Watch and Wait Strategy
Led by Hospital Alemão Oswaldo Cruz · Updated on 2024-11-27
216
Participants Needed
24
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating two different chemotherapy regimens following long-course chemoradiation therapy for patients with distal rectal cancer. The study aims to compare fluoropyrimidine alone versus fluoropyrimidine combined with oxaliplatin in consolidation chemotherapy to determine their effect on tumor response and the potential for organ preservation through a Watch and Wait strategy. This multi-center trial focuses on patients with MRI-defined distal rectal tumors classified as mrT2-3N0-1 and assesses tumor response after 12 weeks from radiotherapy completion.
Participants receive 54 Gy of radiotherapy with daily capecitabine during treatment, followed by consolidation chemotherapy starting one week after radiotherapy ends. One group receives fluoropyrimidine alone, while the other receives fluoropyrimidine plus oxaliplatin, with dosing schedules of either mFOLFOX6 or CAPOX over approximately 12 weeks. Tumor response is centrally reviewed at 12 and 18 weeks, with decisions about continuing organ preservation or proceeding to surgery made by a central committee blinded to treatment assignment.
Throughout the study, participants undergo clinical exams, endoscopic assessments, and high-resolution MRI to monitor tumor changes and response. The primary outcome is the decision to proceed with the Watch and Wait approach based on clinical complete response at 18 weeks post-radiotherapy. Secondary outcomes include surgery-free survival, total mesorectal excision-free survival, distant metastases-free survival, local regrowth-free survival, and colostomy-free survival assessed over three years. The study includes ongoing safety monitoring and follow-up to evaluate long-term outcomes.
CONDITIONS
Brief Title
Chemoradiation and Consolidation Chemotherapy With or Without Oxaliplatin for Distal Rectal Cancer and Watch and Wait
Research Team
R
Rodrigo O Perez, Dr
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
ECOG performance status 0-2 or Karnofsky score 70 or higher
Biopsy-confirmed primary rectal adenocarcinoma accessible by digital rectal exam
Endoscopic documentation of tumor
No evidence of metastatic disease on abdominal and chest CT scans
High-resolution MRI performed with specified protocols including sagittal and axial oblique T2 images
Tumor located at or below 1cm above the anorectal ring on MRI
Tumor stage mrT2 or mrT3 with up to 3 positive lymph nodes (mrN0-1)
Any status of extramural vascular invasion (mrEMVI) and mesorectal fascia involvement (mrMRF) allowed
You will not qualify if you...
Pregnancy
ECOG performance status 3 or higher or Karnofsky score below 70
Unwillingness to provide consent
Presence of metastatic disease excluding internal iliac and obturator lymph nodes
Tumor stage mrT4 or lymph node stage mrN2
Previous pelvic radiation therapy
Existing baseline neuropathy
Current treatment with other anti-cancer drugs or methods
Presence of uncontrolled life-threatening diseases
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - Approximately 17 weeks
Participants receive radiotherapy with daily concomitant capecitabine for 5 weeks, followed by consolidation chemotherapy starting 1 week after radiotherapy ends. Consolidation chemotherapy lasts about 12 weeks with either 5FU plus Oxaliplatin or 5FU alone depending on treatment arm.
Daily visits for radiotherapy over 5 weeks and visits every 2 to 3 weeks during 12 weeks of consolidation chemotherapy
Assessment of Response
Duration - Up to 6 weeks after treatment
Participants undergo endoscopic, digital rectal exam, and MR imaging assessments at 12 weeks and, if applicable, at 18 weeks after radiotherapy to evaluate clinical response and determine further management.
2 visits (at 12 weeks and 18 weeks post-radiotherapy)
Follow-up
Duration - Up to 3 years
Participants are monitored for surgery-free survival, local regrowth, distant metastases, and colostomy-free survival for up to 3 years after treatment.
Periodic visits over 3 years for monitoring
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Phase III Trial Comparing Short-Course Versus Long-Course Radiotherapy Followed by Immunotherapy and Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer
Phase 2 Study on Safety and Effectiveness of Short Course Radiation and CAPOX Chemotherapy Before Surgery for T2 Rectal Cancer
Open-Label Phase 1 Study of DEM301 to Evaluate Safety and Dose in Adults With Advanced Metastatic Colorectal Cancer
Phase I-II Study of PD1 AB122 and Adenosine Receptor AB928 Antagonists with Chemotherapy After Short-Course Radiation for Rectal Cancer
Phase II Study of Beta-Hydroxybutyrate Supplementation with Short-Course Radiotherapy, Immunotherapy, and CAPEOX Chemotherapy in Locally Advanced Rectal Cancer
Randomized Study Comparing Low Volume Transanal Irrigation by Qufora48 IrriSedo MiniGo with Conservative Treatment in Adults with Low Anterior Resection Syndrome
Phase 2 Study Evaluating Botensilimab With Balstilimab as Adjuvant Treatment for Colorectal Cancer Patients With Persistent Circulating Tumor DNA After Surgery and Chemotherapy
Phase II Open-Label Study of Oral Fruquintinib with FOLFIRI for Adults with Metastatic Colorectal Cancer as Second-Line Treatment
Study of How Rectal Cancer Responds to Standard Chemoradiation and Chemotherapy Before Surgery
Phase II Study of Tucatinib and Trastuzumab Combined with Chemotherapy for Locally Advanced HER2-Positive Rectal Cancer
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
A multi-centre randomized controlled trial investigating Consolidation Chemotherapy with and without oxaliplatin in distal rectal cancer and Watch & Wait.
Angelita Habr-Gama, Guilherme Pagin São Julião, Cinthia D Ortega...